Caplin Point Laboratories
Niche, high-return company built on a unique LatAm front-end distribution model now layering on a fast-growing US sterile injectables and ophthalmic franchise.
A full research profile for one company — what it does, how its financials have trended, how the market values it, and a balanced bull/bear/base investment memo.
Scan the top row for the headline numbers, read the charts for trends, check the three gauge scores, then read the auto-generated memo at the bottom. Sources for every figure are linked at the very bottom.
- EBITDA
- — Earnings before interest, tax, depreciation & amortisation — a proxy for operating cash profit.
- PAT
- — Profit After Tax — the bottom-line net profit.
- FCF
- — Free Cash Flow — cash left after running the business and capital spending.
- ANDA
- — Abbreviated New Drug Application — the US FDA filing to sell a generic drug.
Revenue
₹ crore · FY
EBITDA
₹ crore · FY
Margins
EBITDA & PAT margin %
R&D Spend
₹ crore · FY
Free Cash Flow
₹ crore · FY
Revenue Mix
By geography / segment
Quality Score
Growth Score
Regulatory Risk
Snapshot
Business Model
How the company makes money
LatAm front-end branded distribution + scaling US sterile injectables/ophthalmics (Caplin Steriles).
US injectables ramp + LatAm depth
LatAm currency/political & US scale-up
Peer Group
Click to compare
| Peer | Rev CAGR | EBITDA% | ROCE | P/E |
|---|---|---|---|---|
| Caplin Point Laboratories | 29% | 34% | 26% | 28x |
| Rubicon Research | 81% | 20.7% | 39.9% | 104x |
| Ajanta Pharma | 19% | 27% | 32.3% | 36x |
| Neuland Laboratories | 53% | 22% | 19% | 60x |
| Alembic Pharmaceuticals | -5% | 15.2% | 13% | 20x |
Investment Memo
Auto-generated from the data layer — illustrative, not advice
- • US injectables ramp + LatAm depth underpins a 29% 5Y revenue CAGR.
- • Premium 34% EBITDA margin with 26% ROCE signals durable economics.
- • Clean balance sheet (D/E 0.08) funds growth internally.
- • LatAm currency/political & US scale-up.
- • Pricing/NLEM exposure on the domestic book can cap realisation.
- • Re-rating depends on proving R&D/return discipline.
Caplin Point Laboratories screens as a high-quality us generics franchise. With revenue of ₹1.9K Cr growing ~29% and 34% EBITDA margins, the base case is steady compounding driven by us injectables ramp + latam depth, while watching latam currency/political & us scale-up.
Trades at 28x P/E, 22.0x EV/EBITDA and 5.0x P/B. Reasonable versus growth — re-rating optionality if execution improves.
- 1 India IPM outperformance & chronic mix
- 2 Gross-margin trajectory & new-launch contribution
- 3 R&D productivity (filings/approvals per ₹ of R&D)
- 4 Capital allocation — capex payback & M&A discipline
Mix: emerging markets (LatAm + Africa) ~79%, US ~21%. ANDA 48 filed / 38 approved (Caplin Steriles). Near debt-free.